摘要
目的:探讨瑞舒伐他汀联合缬沙坦对糖尿病肾病(DN)患者肾功能及炎性因子表达的影响。方法:60例于我院2017年2月~2018年2月收治的糖尿病肾病患者为研究对象,按照随机数表法分为治疗组和对照组,每组30例。对照组在常规治疗基础上给予缬沙坦,治疗组在对照组治疗基础上加用瑞舒伐他汀。比较两组治疗总有效率,同时比较治疗前后的24h尿蛋白定量、尿白蛋白排泄率(UAER)及血清炎性细胞因子(IL-6、IL-18、TNF-α)水平。结果:治疗组治疗总有效率为96.67%,显著高于对照组的73.33%(χ^2=4.71,P=0.03);治疗后,治疗组24h尿蛋白定量、UAER及各项炎性因子指标均显著低于对照组(P<0.05)。结论:瑞舒伐他汀联合缬沙坦治疗DN可显著改善肾功能,且能够抑制体内炎症基因表达,降低炎性因子浓度,疗效确切,值得在临床推广。
Objective: To investigate the effects of rosuvastatin combined with valsartan on renal function and inflammatory factors in patients with diabetic nephropathy. Methods: Sixty patients with diabetic nephropathy admitted to our hospital from February 2017 to February 2018 were enrolled. The patients were divided into treatment group and control group by random number method, 30 cases each. Patients in the control group were given valsartan on a routine basis, and patients in the treatment group were given rosuvastatin on the basis of the control group. The total effective rate of treatment was compared between the two groups. The 24h urine protein quantitation, urinary albumin excretion rate(UAER)and serum inflammatory cytokines(IL-6, IL-18, TNF-α)levels were compared before and after treatment. Results: The total effective rate of treatment group was 96.67%,which was significantly higher than that of the control group 73.33%(χ^2=4.71,P=0.03). After treatment, the treatment group had 24h urine protein quantitation, urinary albumin excretion rate and various inflammatory factors. The indexes were significantly lower than the control group(P<0.05). Conclusion: Rosuvastatin combined with valsartan in the treatment of DN can significantly improve renal function, and can inhibit the expression of inflammatory genes in vivo, reduce the concentration of inflammatory factors, and the curative effect is exact,which is worthy to promote.
作者
邝凤婵
刘燕琼
黄裕明
陈红德
Kuang Fengchan;Liu Yanqiong;Huang Yuming;Chen Hongde(Shijing People's Hospital,Baiyun District,Guangzhou,Guangdong,510430)
出处
《北方药学》
2019年第10期6-7,共2页
Journal of North Pharmacy
关键词
瑞舒伐他汀
缬沙坦
糖尿病肾病
炎性因子
Rosuvastatin
Valsartan
Diabetic nephropathy
Inflammatory factor
